Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) – Pipeline Review, H2 2017’, provides in depth analysis on Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Central Nervous System, Infectious Disease, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology under development targeting Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects

The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BeyondSpring Pharmaceuticals Inc

Conatus Pharmaceuticals Inc

New World Laboratories Inc

Novartis AG

Pharmedartis GmbH

Sanofi

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Overview 7

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 17

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Companies Involved in Therapeutics Development 25

BeyondSpring Pharmaceuticals Inc 25

Conatus Pharmaceuticals Inc 25

New World Laboratories Inc 26

Novartis AG 26

Pharmedartis GmbH 27

Sanofi 27

Shire Plc 28

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Drug Profiles 29

1G3-Cu - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BaxB-01 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BaxG-03 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BaxM-159 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

emricasan - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

emricasan - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

flavokawain A - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Fusion Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

HaA-4 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

IDN-7314 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

MBRI-001 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

NWL-53 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

plinabulin - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule to Activate Caspase-3 for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Dormant Products 59

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Discontinued Products 62

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Product Development Milestones 63

Featured News & Press Releases 63

Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia 63

Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline 63

Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting 64

Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco 64

Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 65

Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis 65

Jul 06, 2017: China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention 66

Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 67

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference 68

Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego 69

May 08, 2017: BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017 69

Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention 70

Mar 22, 2017: BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017 71

Mar 20, 2017: BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia 72

Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16

Number of Products under Investigation by Universities/Institutes, H2 2017 17

Products under Investigation by Universities/Institutes, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 25

Pipeline by Conatus Pharmaceuticals Inc, H2 2017 26

Pipeline by New World Laboratories Inc, H2 2017 26

Pipeline by Novartis AG, H2 2017 27

Pipeline by Pharmedartis GmbH, H2 2017 27

Pipeline by Sanofi, H2 2017 28

Pipeline by Shire Plc, H2 2017 28

Dormant Products, H2 2017 59

Dormant Products, H2 2017 (Contd..1), H2 2017 60

Dormant Products, H2 2017 (Contd..2), H2 2017 61

Discontinued Products, H2 2017 62

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 19

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports